South Korea Nicotine Replacement Therapy Market Overview,2030

The nicotine replacement therapy (NRT) market in South Korea has grown steadily over the past two decades, supported by robust public health policies, a relatively high smoking prevalence among men, and government-backed cessation initiatives. South Korea historically had one of the highest male smoking rates in the OECD, with over 60% in the early 1990s, though this has declined to around 31% by 2023 due to aggressive tobacco control measures. NRT was introduced in the late 1990s, initially through patches and gums marketed by multinational pharmaceutical companies such as Johnson & Johnson and GlaxoSmithKline. Early adoption was limited due to cultural perceptions that quitting smoking was more about willpower than medical assistance. However, in 2005, the Ministry of Health and Welfare launched its National Smoking Cessation Program, making NRT available free of cost or subsidized through public health centers. This marked a significant turning point, driving wider accessibility and reducing economic barriers. Over the years, patches, gums, and lozenges have become standard tools offered by health authorities and private pharmacies. As of 2024, South Korea’s NRT market is estimated at USD 90–120 million, with patches dominating due to their integration into structured cessation programs. Despite progress, challenges persist, as South Korea’s smoking prevalence, though declining, remains among the highest in developed Asia. The evolution of the market reflects a strong link between government-led interventions, cultural attitudes, and the expansion of consumer-driven health choices, positioning NRT as a key component of the nation’s long-term tobacco reduction strategy.

According to the research report, ""South Korea Nicotine Replacement Therapy Market Overview, 2030,"" published by Bonafide Research, the South Korea Nicotine Replacement Therapy market is anticipated to add to USD 3.15 Billion by 2025–30.South Korea offers significant growth opportunities for NRT as smoking cessation remains a national health priority, backed by both government subsidies and rising consumer health awareness. Regulatory oversight is managed by the Ministry of Food and Drug Safety (MFDS), which approves NRT products as pharmaceuticals and ensures quality and labeling standards. NRT products are integrated into national cessation clinics, often provided at little or no cost for participants in government programs, creating strong baseline demand. However, private sector opportunities exist in expanding premium products such as combination therapies and faster-acting delivery formats. Market trends indicate growing consumer preference for convenience-driven formats like lozenges and oral sprays, complementing the traditional dominance of patches. Digital health is also becoming an innovation driver, with South Korea’s advanced telemedicine and app ecosystem supporting integrated cessation programs where NRT is paired with behavioral support via mobile platforms. Strategic recommendations include strengthening the private retail channel for NRT, diversifying beyond standard products into next-generation therapies, and improving awareness among younger smokers, who increasingly use heat-not-burn tobacco and may require tailored cessation interventions. Opportunities also lie in workplace wellness programs, particularly in South Korea’s corporate sector, where smoking prevalence remains high among male employees. A potential barrier is competition from heat-not-burn devices like IQOS, which are legally available and marketed as reduced-risk alternatives, drawing consumers away from NRT. To remain competitive, stakeholders should position NRT as a medically validated, cost-effective tool with long-term efficacy, supported by integration into South Korea’s digital health ecosystem and reimbursement models.

The nicotine alternatives landscape in South Korea is unique, as it includes all three major categories: NRT, e-cigarettes, and heat-not-burn (HnB) tobacco products. Among these, heat-not-burn devices hold the largest share, with South Korea being one of the first major global markets to adopt IQOS and similar products from Philip Morris International and KT&G. Since their introduction in 2017, HnB products have gained rapid acceptance, with nearly 15% of adult male smokers switching to these alternatives by 2023. E-cigarettes, both nicotine-containing and nicotine-free, are available but face regulatory scrutiny and declining popularity after health concerns in 2019 linked to vaping-associated lung injuries. NRT, by contrast, occupies a niche as the only clinically validated cessation tool, offered in multiple forms such as patches, gums, and lozenges. Patches dominate due to government-provided programs, while gums and lozenges are popular in retail pharmacies. Despite the competitive presence of HnB and e-cigarettes, NRT remains essential in structured cessation clinics, where it is bundled with counseling. However, consumer-driven uptake is more limited compared to these newer alternatives, particularly among younger smokers. This segmentation indicates a polarized market: HnB products attract consumers seeking reduced-risk alternatives, while NRT targets those committed to quitting entirely. Growth potential exists in positioning NRT as complementary to alternative products, for example, helping HnB users eventually transition to full cessation. With South Korea’s strong consumer appetite for technologically advanced solutions, innovations like oral sprays and dissolvable strips could enhance NRT’s competitiveness in this diverse product landscape.

Sales of NRT in South Korea are split between over-the-counter (OTC) and prescription-based channels, though both play distinct roles. OTC sales dominate in pharmacies, convenience stores, and retail chains, where consumers can purchase gums, lozenges, and patches without consulting a physician. This accessibility supports consumer autonomy and appeals to smokers who prefer self-directed quitting attempts. Prescription-based sales are strongly supported by the government’s National Smoking Cessation Program, which provides NRT free of charge or heavily subsidized at public health centers. Participants receive a combination of prescription NRT and behavioral counseling, making this channel an essential driver of structured quitting success. The balance between OTC and prescription channels highlights South Korea’s dual-market dynamic: OTC sales sustain consumer convenience, while prescription channels underpin public health impact. Currently, OTC channels account for approximately 65–70% of sales value, while prescription-based distribution contributes significantly to volume through subsidies. Opportunities exist to strengthen prescription-based adoption by expanding eligibility to younger smokers and integrating cessation programs into corporate wellness initiatives. Meanwhile, OTC channels could benefit from greater marketing efforts, especially in urban centers where consumer awareness and spending capacity are high. Challenges include competition from alternative nicotine delivery systems, which are marketed outside traditional OTC and prescription frameworks, diverting potential demand. Long-term, aligning both channels through hybrid approaches—such as digital prescription programs connected to e-pharmacies—can further integrate NRT into South Korea’s evolving healthcare and consumer health landscape, ensuring sustained adoption across diverse smoker profiles.

Distribution of NRT in South Korea is primarily driven by offline channels, though online sales are expanding rapidly. Pharmacies remain the cornerstone of offline distribution, offering both OTC products and prescription-based NRT under government programs. Convenience stores also stock popular products like gums, providing consumers with accessible options during routine purchases. Hospitals and public health centers distribute prescription NRT free or at subsidized rates, further strengthening the offline channel’s dominance. Online distribution, however, has gained traction in recent years, fueled by South Korea’s advanced e-commerce infrastructure and widespread smartphone penetration. Platforms like Coupang, Gmarket, and pharmacy-linked delivery services now offer NRT with doorstep delivery, appealing to younger, tech-savvy consumers. Online channels also benefit from providing discreet purchasing options, reducing stigma associated with tobacco use or cessation attempts. The COVID-19 pandemic accelerated this shift, as many consumers moved to digital health and e-pharmacy platforms for convenience. Despite this growth, offline channels still account for more than 75% of total sales, given their deep-rooted presence and role in public health distribution. Going forward, hybrid models integrating online ordering with offline pickup, supported by South Korea’s efficient logistics ecosystem, will reshape the market. Strategic opportunities lie in bundling NRT sales with digital cessation tools, such as mobile apps and teleconsultations, to create holistic support ecosystems. As South Korea continues to advance toward a digitally integrated healthcare model, online distribution is expected to grow at double-digit rates, steadily balancing the dominance of offline channels and redefining consumer access to NRT.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Nicotine Replacement Therapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Nicotine Replacement Therapy
• E-cigarettes
• Heat-not-burn tobacco products
By Nicotine Replacement Therapy
• Nicotine Gums
• Nicotine Lozenges
• Nicotine Nasal Sprays
• Nicotine Pouches
• Others (Nicotine Patches, Nicotine Inhalers & Others)
By Sales Type
• Over-the-Counter (OTC)
• Prescription-Based

By Distribution Channel
• Offline
• Online
Show more